137 related articles for article (PubMed ID: 17907062)
1. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
Wang Y; Tomlinson B
Curr Opin Investig Drugs; 2007 Oct; 8(10):849-58. PubMed ID: 17907062
[TBL] [Abstract][Full Text] [Related]
2. Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
van Poelje PD; Potter SC; Erion MD
Handb Exp Pharmacol; 2011; (203):279-301. PubMed ID: 21484576
[TBL] [Abstract][Full Text] [Related]
3. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
Schimke K; Davis TM
Curr Opin Investig Drugs; 2007 Apr; 8(4):338-44. PubMed ID: 17458185
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
van Poelje PD; Potter SC; Chandramouli VC; Landau BR; Dang Q; Erion MD
Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
[TBL] [Abstract][Full Text] [Related]
6. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
Kitas E; Mohr P; Kuhn B; Hebeisen P; Wessel HP; Haap W; Ruf A; Benz J; Joseph C; Huber W; Sanchez RA; Paehler A; Benardeau A; Gubler M; Schott B; Tozzo E
Bioorg Med Chem Lett; 2010 Jan; 20(2):594-9. PubMed ID: 19969452
[TBL] [Abstract][Full Text] [Related]
7. CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Yoshida T; Okuno A; Izumi M; Takahashi K; Hagisawa Y; Ohsumi J; Fujiwara T
Eur J Pharmacol; 2008 Dec; 601(1-3):192-7. PubMed ID: 19014931
[TBL] [Abstract][Full Text] [Related]
8. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
Giannoukakis N
Curr Opin Investig Drugs; 2007 Oct; 8(10):842-8. PubMed ID: 17907061
[TBL] [Abstract][Full Text] [Related]
9. MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Erion MD; van Poelje PD; Dang Q; Kasibhatla SR; Potter SC; Reddy MR; Reddy KR; Jiang T; Lipscomb WN
Proc Natl Acad Sci U S A; 2005 May; 102(22):7970-5. PubMed ID: 15911772
[TBL] [Abstract][Full Text] [Related]
10. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
11. Insulin glulisine. Aventis Pharma.
Barlocco D
Curr Opin Investig Drugs; 2003 Oct; 4(10):1240-4. PubMed ID: 14649217
[TBL] [Abstract][Full Text] [Related]
12. CLX-0901 (Calyx Therapeutics).
Barlocco D
Curr Opin Investig Drugs; 2001 May; 2(5):650-3. PubMed ID: 11569941
[TBL] [Abstract][Full Text] [Related]
13. E1-INT (Transition Therapeutics/Novo Nordisk).
von Herrath M
Curr Opin Investig Drugs; 2005 Oct; 6(10):1037-42. PubMed ID: 16259225
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
[TBL] [Abstract][Full Text] [Related]
15. Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IV.
Epstein BJ
Curr Opin Investig Drugs; 2007 Apr; 8(4):331-7. PubMed ID: 17458184
[TBL] [Abstract][Full Text] [Related]
16. Eligen insulin--a system for the oral delivery of insulin for diabetes.
Hoffman A; Qadri B
IDrugs; 2008 Jun; 11(6):433-41. PubMed ID: 18509785
[TBL] [Abstract][Full Text] [Related]
17. Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Dang Q; Brown BS; Liu Y; Rydzewski RM; Robinson ED; van Poelje PD; Reddy MR; Erion MD
J Med Chem; 2009 May; 52(9):2880-98. PubMed ID: 19348494
[TBL] [Abstract][Full Text] [Related]
18. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
Drew BG; Calkin AC
Curr Opin Investig Drugs; 2007 Apr; 8(4):324-30. PubMed ID: 17458183
[TBL] [Abstract][Full Text] [Related]
19. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
20. New hepatic targets for glycaemic control in diabetes.
Agius L
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):587-605. PubMed ID: 18054737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
